Health Care Facilities

CR MEDICAL

SAMR Approves China Resources for Unconditional Acquisition of Beijing Aerospace Medical Company

CR MEDICAL released FY2025 9 Months Earnings on March 24, 2026 (BJT) with actual revenue of HKD 7.441 B and EPS of HKD 0.3563

CR MEDICAL released FY2025 Q3 earnings on March 24, 2026 (BJT) with actual revenue HKD 0 and actual EPS HKD 0

China Resources Healthcare Announces 2025 Annual Results, Revenue and Profit Declined

CR MEDICAL released FY2025 Q4 earnings on March 24 During-Market (BJT), actual revenue HKD 2.586 B, actual EPS HKD 0.0667

CR MEDICAL released FY2025 earnings on March 24 During-Market (BJT), actual revenue HKD 10.03 B (forecast HKD 10.89 B), actual EPS HKD 0.4262 (forecast HKD 0.4484)

CR MEDICAL to release FY2025 earnings on March 24 during market hours (BJT), forecast revenue HKD 10.71 B, EPS HKD 0.4409

Fidelity International Reduces Holding in China Resources Medical by 797,500 Shares

CR MEDICAL released FY2025 Q1 earnings on August 26 (BJT), actual revenue HKD 2.423 B, actual EPS HKD 0.1445

CR MEDICAL released FY2025 Q2 earnings on August 26 During-Market (BJT), actual revenue HKD 2.476 B, actual EPS HKD 0.1469

CR Medical released FY2025 Semi-Annual Earnings on August 26 During-Market BJT, Actual Revenue HKD 4.899 B, Actual EPS HKD 0.2907

CR MEDICAL to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

China Resources Healthcare Sees Profit Slump of 55% to 60% in First Half

Morgan Stanley downgrades Huaren Healthcare target price to HKD3

China Resources Healthcare Files Lawsuit for Yanshan IOT Agreement Dispute

China Resources Healthcare to Pay Final Dividend of 8.9 HK cents

CICC Downgrades China Resources Medical's 2025 Net Profit Forecast to 566 Million Yuan, Maintains Outperform Rating

CR Medical released FY2024 9 Months Earnings on March 25 (BJT), with actual revenue of 8.074 B HKD and actual EPS of 0.4247 HKD

CR Medical released FY2024 Q3 earnings on March 25 (BJT), with actual revenue of 2.704 B HKD and EPS of 0.0578 HKD

China Resources Medical Holdings Releases 2024 Annual Results, Revenue of 9.855 Billion Yuan, Down 2.5% Year-on-Year

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

Ordinary dividend (cash)

Ex Date: 2026.06.15, Cash dividend 0.0954 HKD

01515

CICC published a research report stating that CR MEDICAL is steadily developing and actively implementing measures to reduce costs and improve efficiency, while also strengthening discipline. The bank maintains its net profit forecast for 2026 at RMB 499 million and adds a new net profit forecast for 2027 at RMB 510 million. Due to the decline in the valuation of the H-share medical services sector, the bank has lowered the target price for CR MEDICAL by 18.8% to HKD 4.06, maintaining its "outperform" rating

AASTOCKS

In "Major Banks," CICC lowered the target price for CR MEDICAL to 4.06 yuan with a rating of "Outperform the Market."

CR MEDICAL announced its 2025 annual performance, with revenue of RMB 9.176 billion, a year-on-year decrease of 6.9%. It recorded a net profit of RMB 496 million, down 12.4%, with earnings per share of 39 cents. The final dividend is 8.4 cents

"Performance" CR MEDICAL's annual net profit is RMB 496 million, down 12.4%, with a final dividend of 8.4 cents

513120

510660

512010

516610

02841

159929

589720

China Resources Medical Profit Slips as Revenue Declines but Dividends Edge Higher

Tip Ranks

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

GX CN MEDTECH

China Universal 800 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

China Resources Medical Profit Slips as Revenue Declines but Dividends Edge Higher

159883

01931

ETHK LABS INC. issued a profit warning, expecting a profit of no more than RMB 42.2 million for the fiscal year 2025, compared to RMB 260 million recorded in the previous year. The decline in profit is mainly due to intensified competition in the in vitro diagnostics industry, resulting in a decrease in gross profit of RMB 185 million due to a decline in gross margin; administrative expenses increased by RMB 68 million, primarily due to increased professional fees related to the group's planned dual listing in the United States; and financing costs increased by approximately RMB 24.5 million

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ETHK LABS INC.

"Profit Warning" CR MEDICAL's profit expected to decline, with a maximum profit of 42.2 million RMB last year

CR MEDICAL announced that due to changes in work arrangements, Yang Min has resigned from the position of Executive Director and Chief Financial Officer, effective February 27. On the same day, Wang Yuexing was appointed as the company's Executive Director

CR MEDICAL Chief Financial Officer Resigns

CR MEDICAL issued a profit warning, expecting profits for the fiscal year 2025 to be between RMB 467 million and RMB 516 million, a decrease of 8.9%-17.5% compared to the previous year. Excluding a one-time compensation of RMB 210 million received during the year, profits would decline by 37.6%-43.5%. This is mainly affected by the decrease in average medical expenses under the medical insurance system, leading to a decline in operating profits of member medical institutions, as well as a reduction in the scale of the company's IOT (Investment - Operation - Transfer model) business

"Profit Warning" CR MEDICAL forecasts a profit decline of 8.9%-17.5% for last year

01313

00836

01109

02460

00291

600062

Han Song, a member of the Party Committee and Deputy General Manager of China Resources (Group) Co., Ltd., is suspected of serious violations of discipline and law, has voluntarily surrendered, and is currently undergoing disciplinary review and supervisory investigation by the Central Commission for Discipline Inspection and the National Supervisory Commission. (CCTV News)

Wallstreetcn

CR BLDG MAT TEC

CHINA RES POWER

CHINA RES LAND

CR BEVERAGE

CHINA RES BEER

CR Double-Crane

Han Song, Deputy General Manager of China Resources Group, is under investigation

China Resources Medical Holdings Co (HK:1515) has projected a profit drop for 2025, estimating earnings attributable to shareholders between RMB467 million and RMB516 million, a decline of 8.9% to 17.5% from 2024. The decrease is attributed to lower medical insurance fees and a reduction in its invest-operate-transfer business. However, the company reports improved performance in the second half of 2025, with reduced bank borrowings and increased healthcare management revenues from new intelligent services. The latest analyst rating for the stock is a Sell with a price target of HK$3.00.

China Resources Medical flags 2025 profit drop but highlights shift to intelligent healthcare services

159837

512170

Huahui Health's Libevitug injection has received conditional approval from China's NMPA as the first treatment for chronic hepatitis D. This human monoclonal antibody targets the PreS1 domain of HBV and HDV, blocking viral entry into liver cells. Libevitug addresses a significant clinical gap, especially in China, where over 75 million people suffer from chronic hepatitis B. The drug showed superior efficacy in clinical trials, with a combined response rate of 44.1% and a virological response rate of 60%. It aligns with China's goals to improve hepatitis diagnosis and treatment by 2030.

prnewswire

E Fund CSI Biotechnology Theme ETF

iShares Biotechnology ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

VanEck Biotech ETF

Hwabao WP CSI Medical Service ETF

Proshares UltraShort Nasdaq Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

03:18 ET
			
			
				Libevitug Approved in China as First-in-Class Treatment for Hepatitis D

On January 27, 2026, Huahui Health revealed that the China National Medical Products Administration (NMPA) has provided conditional approval for its Libevitug injection to address chronic hepatitis D virus infection in adults, with or without compensated cirrhosis.

Unusual Whales

China approves Huahui Health's Libevitug injection for treating hepatitis D; first of its kind; NMPA grants conditional approval.

CR MEDICAL(01515.HK)

In "Major Banks," CICC lowered the target price for CR MEDICAL to 4.06 yuan with a rating of "Outperform the Market."

"Performance" CR MEDICAL's annual net profit is RMB 496 million, down 12.4%, with a final dividend of 8.4 cents

China Resources Medical Profit Slips as Revenue Declines but Dividends Edge Higher

"Profit Warning" CR MEDICAL's profit expected to decline, with a maximum profit of 42.2 million RMB last year

CR MEDICAL Chief Financial Officer Resigns

"Profit Warning" CR MEDICAL forecasts a profit decline of 8.9%-17.5% for last year

Han Song, Deputy General Manager of China Resources Group, is under investigation

China Resources Medical flags 2025 profit drop but highlights shift to intelligent healthcare services

03:18 ET Libevitug Approved in China as First-in-Class Treatment for Hepatitis D

China approves Huahui Health's Libevitug injection for treating hepatitis D; first of its kind; NMPA grants conditional approval.

Trending